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Abstract. Background/Aim: Development of patient-derived
three-dimensional (3D) organoid cultures is an emerging
technique in the field of precision oncology. We aimed to
integrate on-site adequacy evaluation using cytology into the
tumor organoid development workflow to ensure precise
characterization and growth of these cultures. Patients and
Methods: Cancer patients were consented to a Precision
Medicine trial. Fresh tissue was procured for genomic analyses
as well as organoid development. Fresh tissue destined for
organoid development was evaluated by preparing on-site
cytology smears to ensure that only lesional tissue would be
submitted for further cell culture work. Results: Cytology
preparations were made from 64 different tumor samples and
evaluated prior to tissue submission for organoid development.
In 53 (82.2%) of those tumor samples, the cytology preparation
was diagnostic, thus providing adequate material for organoid
development. Conclusion: Characterizing the tissue prior to
submission for organoid development ensures submission of
lesional tissue only. Furthermore, it is a cost-effective method
that can help document patient diagnosis. This can be of
importance in biopsies, since the tissue submitted for organoid
development cannot be retrieved for clinical diagnosis
afterwards. Our findings in this pilot study led to the
implementation of on-site cytological evaluation in the tumor
organoid development workflow at the Englander Institute for
Precision Medicine, NY, USA. 
Personalized medicine, also referred to as Precision Medicine
(PM), is the approach to treat a patient’s disease by taking
into account the molecular landscape of the individual tumor
or disease process. In addition to its role in oncology, PM is
also employed in the treatment of other chronic conditions
such as autoimmune disorders. In the United States, the
Precision Medicine Initiative® was launched by President
Barack Obama in early 2015 in order to facilitate
individualized patient care. Recently, the National Institute of
Health (NIH) awarded $55 million to enroll one million
patients in a multi-institutional precision medicine trial (1). 
In the field of Precision Oncology, the development of
patient-derived 3D tumor organoid cultures is an emerging
model that can be a valuable tool for predictive in vitro drug
testing (2). Although cell lines have long been established
for preclinical drug testing, they do not sufficiently
recapitulate the innate tumor heterogeneity and therefore the
genomic complexity. Organoid cultures are thus the
preferable method for predictive drug testing (3). Organoids
are derived from stem cells and are self-organizing and self-
renewing (4). Since organoids maintain the genetic
representation of a patient’s tumor, they are a readily
available source of high-quality DNA and RNA for next
generation sequencing (NGS). In order to initiate organoid
development, fresh tumor tissue is collected and processed
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in a time sensitive manner. Weeber et al. successfully
cultured organoids in 10 of 14 cases (71%) of metastatic
colorectal carcinoma (5). Successful generation of organoid
cultures was higher (up to 90%) in samples from primary
tumors when compared with metastases (6).
Organoid development is a time- and cost-intense
process. As yet, no cost estimate per organoid development
has been published. Organoids are usually propagated in
Matrigel Matrix (Corning Inc. USA), which closely
resembles extracellular matrix. It provides a scaffold for
cells to grow and proliferate (7). Matrigel is a relatively
expensive medium priced at approximately $318 per
bottle. Costs for technical staff adds to the expenditure for
cell culture infrastructure and consumables. Submitting
tissue for organoid development “blindly”, i.e. without
prior characterization, can result in spending money and
time propagating benign organoids. Submitting only
lesional tissue for further processing is therefore
paramount. Rapid on-site evaluation (ROSE) is a common
practice in cytopathology that assesses tissue samples for
adequacy of material for diagnostic purposes. We have
recently shown, that cytological evaluation of organoids
within a few weeks into their development can
successfully characterize them (8). In the present study, we
aimed to integrate on-site cytological evaluation during
tissue collection to identify viable tumor for organoid
development and guide decision-making on the early fate
of these organoids. 
Materials and Methods
Between October 2015 and July 2016 tumor tissue from patients
diagnosed with a variety of malignant and benign tumors was
collected as described previously (9). The Institutional Review Board
at Weill Cornell Medical College approved the protocol for tissue
collection for the overarching Precision Medicine clinical trial
(IRB#1305013903). Written informed consent was obtained from all
enrolled patients. Tissue was triaged according to pre-defined
operational procedures with clinical diagnosis and WES/RNA
sequencing being the most important considerations (Figure 1).
From the remainder of the tissue, a very small amount (less than 
0.5 mm) of a grossly suspicious area was used to prepare a cytology
smear as described before (8). The air-dried smear was then stained
with Diff-Quik staining solution (Siemens Medical Solutions USA,
INC, Malvren, PA, USA) and reviewed by a board-certified
cytopathologist (RR). A positive diagnosis resulted in submission of
the tissue for further organoid development. A negative interpretation
resulted in non-submission of tissue for organoid growth. The tissue
was instead added to the tissue destined for WES. These tissue
samples were snap-frozen and frozen sections were reviewed for
their overall tumor cell content before proceeding to DNA-extraction
for WES. IBM SPSS Statistics, Version 24.0 (IBM Corporation,
Armonk, NY, USA) software was used for statistical analysis. 
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Figure 1. Fresh tissue collection workflow at the Institute for Precision Medicine (IPM), NY, USA. Consented patients undergo a repeat, usually
CT-guided biopsy or a surgical resection. Tissue is triaged and prioritized for surgical pathology to establish a diagnosis. Part of the remaining
tissue is snap-frozen to preserve DNA and RNA for whole-exome sequencing (WES) and RNASeq. The remainder of the tissue will be submitted for
organoid development if on-site cytologic assessment is positive. However, if on-site cytology is negative, the tissue is not discarded but instead
added to the fresh tissue destined for WES. These samples are snap-frozen and frozen sections are reviewed. If the tumor cell content is sufficient,
DNA and RNA will be extracted and send for sequencing.  
Results
Sixty-four fresh tumor tissue samples were collected. Patient
tissue samples were procured from 2 (3.1%) benign and 62
(96.9%) malignant tumors. Thirty-seven (57.8%) samples
were taken from core biopsies, and 27 (42.2%) from
resection specimens. Histology of primary tumors included
36 (56.3%) adenocarcinomas from a variety of primary sites
(13 prostate, 23 gastrointestinal). In addition, 8 (12.5%)
urothelial carcinomas, 5 (7.8%) renal cell carcinomas, 6
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Figure 2. Examples of positive cytology, concurrent histology and subsequent organoids: Small-cell prostate cancer, right humerus metastasis. Air-
dried DQ stained smear, 40× (A), histology (H&E), 20× (B), 3D organoid in cell culture, 5× (C). High-grade invasive urothelial carcinoma of the
bladder (post-neoadjuvant treatment), bladder resection. Air-dried DQ stained smear, 20× (D), histology (H&E), 20× (E), 3D organoid in cell
culture, 5× (F). Metastatic prostatic adenocarcinoma, left iliac bone biopsy. Air-dried DQ stained smear, 40× (G), histology (H&E), 20× (H), 3D
organoid in cell culture, 5× (I).
(9.4%) mesenchymal tumors, 2 (3.1%) primary brain tumors,
2 (3.1%) small cell carcinomas of prostatic origin and 2
(3.1%) squamous cell carcinomas (1 esophageal primary, 1
anal primary) and one papillary thyroid carcinoma (1.6%)
were collected. Benign tumor types included one ovarian
fibroma and one schwannoma (3.1%), which were collected
due to the clinical suspicion of malignancy in these cases. 
A total of 53 (82.2%) cytology smears contained tumor
cells sufficient for diagnosis (Figure 2). This sensitivity is
comparable with data reported in the literature on ROSE (10).
Eleven (17.2%) cytology smears were negative, of which four
were from bone biopsies, three from lymph node biopsies, two
from liver biopsies, one from a peritoneal biopsy and one from
a pleura biopsy. All cytology smears from resection specimens
were diagnostic. The cytologic evaluation of one such
negative bone biopsy was initially interpreted as indeterminate
due to the presence of few “atypical” cells, and the concurrent
core biopsy was reported as negative for malignant cells. The
tissue in this case was initially suspended in cell culture media
for less than 24 hours, but was finally processed as a formalin-
fixed paraffin embedded (FFPE) block following the final core
biopsy pathology.
Of the 53 tumor samples that were processed for organoid
development, 36 (67.9%) contained viable tumor cells that
formed globular structures in cell culture. Failure of organoid
growth in the remaining 17 (32.1%) cases was mostly related
to small biopsy sample size and tumor samples of prostatic
origin. 
Discussion
We have previously shown that cytology smears are a useful
diagnostic tool in the field of organoid research (8). In the
present study, we demonstrate that determining the adequacy
of tissue using cytology smears prior to submission for
organoid development is feasible and effective. It ensures
that only lesional tissue and not tissue contaminants are
grown, thereby improving process efficiency in terms of time
and cost. Preparation of a cytology smear is a relatively
simple and less expensive technique especially if one is
trained in good smear preparation techniques. In a small
series of ten tumor organoids from patients with pancreatic
cancer (11), two organoid cultures failed to grow. The
authors in this series attributed this failure to necrosis
following neoadjuvant therapy in one case. In the other case,
benign stromal overgrowth led to the failure of the cultures
(11). We hypothesize, that in both above cases, pre-organoid
cytology could have revealed the absence of viable tumor
cells before submitting the tissue for cell culture work.
In general, when tumor tissue is submitted for organoid
development, it cannot be retrieved and reprocessed for
diagnostic evaluation. In addition, the sample that is provided
for organoid development can be limited in size with minimal
tumor volume. Cytologic assessment of the tumor tissue prior
to submission for organoid development can be of added
value in determining the quality of the sample. 
We and others have shown, that the molecular make-up of
the primary tumor genomic as well as transcriptomic
alterations are preserved throughout organoid propagation
(Dr. Chantal Pauli, personal communication) (12). The
ability to capture tumor heterogeneity makes organoids
superior to traditional cancer cell lines (13, 14). Therefore,
organoids can be an excellent tool in the future for ex vivo
drug screening to select targeted therapy (15, 16). Testing
therapeutic agents in preclinical 3D cell cultures may also
help reduce unnecessary side-effects and might reduce
treatment costs. If several organoids from the same patients
are maintained in culture, treatment induced selection
processes and potential resistant mechanisms can be studied
(17). In addition, organoids can be propagated from a variety
of highly prevalent primary tumors like colorectal and
pancreas cancer, thus addressing the needs of a large number
of patients (18). However, organoid development has not
been implemented in clinical practice yet (19). Further
studies analyzing cost-benefit ratio, turnaround time and
survival are necessary. 
In summary, our pilot study demonstrates the efficacy of
on-site cytology in the context of precision oncology and
organoid development. These results have led to the
implementation of on-site cytology in our workflow at the
Englander Institute for Precision Medicine.
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